Company news
CervoMed Inc. news in 2024
CervoMed Inc.'s news releases, calls and decks from 2024, newest first.
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2024
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
December 9, 2024
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
November 26, 2024
CervoMed Announces Key Senior Leadership Appointments
November 12, 2024
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 11, 2024
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
November 7, 2024
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
November 3, 2024
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
October 28, 2024
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
October 14, 2024
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 11, 2024
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
July 28, 2024
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
July 10, 2024
CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
June 23, 2024
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
June 10, 2024
CervoMed to Appoint William Elder as Chief Financial Officer
May 19, 2024
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 14, 2024
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
March 31, 2024
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
March 27, 2024
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
March 4, 2024
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
February 19, 2024
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
February 6, 2024
Decks in 2024
- Investor Presentation (December 2024)
Investor deck · 13 slides · Dec 10, 2024